• Clinical and Experimental Pediatrics
• /
• 제53권3호
• /
• pp.414-419
• /
• 2010

목 적 : 제 1형 당뇨병에서 보이는 자가 항체와 질환의 진행에 따른 변화와의 관계는 여러 연구에서 보고되었고, 항체가가 높을수록 진행의 정도가 급격하였다. 따라서 진단 당시에 시행한 자가 항체의 발현 여부에 따라 임상 발현 정도가 다를 것으로 생각하여, 자가 항체 유무에 따라 임상 양상과 검사 소견의 차이가 있는지를 확인하고자 하였다. 방 법 : 1999년 4월부터 2008년 3월까지 3개 대학병원에 내원하여 제 1형 당뇨병으로 진단받은 18세 미만 환자 중 처음 진단 당시에 췌장 자가 항체인 GADA 혹은 IAA의 검사를 시행하였던 96명에서 진단 당시 시행한 혈액 검사 및 임상 양상을 항체 그룹에 따라 나누어 비교 분석하였다. 결 과 : GADA는 87명의 환자에서 검사가 이루어 졌고, 이 중 48명(55.2%)에서 양성을 보였다. IAA는 88명 중 35명(39.8%)이 양성을 보였다. 두가지 항체를 모두 검사한 환자는 83명이었고, 이 중 22.8%에서 두 항체가 모두 검출되었고, 38.6%에서는 모두 음성을 보였다. 1가지 이상의 항체를 갖는 환자군에서는 음성군에 비해 비교적 어린 나이에 당뇨병이 발생하였고, 낮은 BMI, 낮은 혈청 교정 Na 수치 및 낮은 혈청 오스몰농도를 보였다(P <0.05). 자가 항체 중 GADA 양성군과 음성군 사이의 검사소견 상에서도 같은 차이를 보였다. 그러나 IAA 항체 유무에 따른 비교에서는 발생 연령이외는 두 군사이에 임상 및 검사소견상 유의한 차이를 볼 수 없었다. 결 론 : 항체 양성군과 음성군 사이에서 보이는 대사적 결과의 차이는 비교적 적었으나 GADA와 IAA 항체의 양성율은 어린 연령에서 높았다. 따라서 비교적 어린 연령에 발생하는 1형 당뇨병에서는 질환을 처음으로 진단할 때자가 항체 유무를 확인하고, 만약 항체가 확인되면 향후 집중적인 인슐린 치료를 시행하여 보다 좋은 예후를 유도하는데 도움이 될 수 있을 것이다.

• 한국환경성돌연변이발암원학회:학술대회논문집
• /
• 한국환경성돌연변이발암원학회 2002년도 Molecular and Cellular Response to Toxic Substances
• /
• pp.178-179
• /
• 2002

• 한국임상수의학회지
• /
• 제23권2호
• /
• pp.149-152
• /
• 2006

The canine thyroglobulin autoantibody assay is to be used for the diagnosis of autoimmune thyroid disease in dogs. Antithyroglobulin antibodies are present in about 50 percent of hypothyroid dogs. In this report, the sera of the five canine patients ($P1{\sim}P5$) referred to the Veterinary Medical Teaching Hospital in Seoul National University were assessed by T4, TSH and thyroglobulin autoantibody (TgAA). P1 was diagnosed as severe hypothyroidism since he showed very high TSH levels with low T4 values. P2 and P3 born with a genetic predisposition were assessed as normal in thyroid function. P4 was normal, but needed follow-up examination for TgAA assay. P5 showed the positive result in TgAA assay, so it was diagnosed as autoimmune thyroiditis. As the cases above show, not only T4 and TSH, but also TgAA assay to be considered for more accurate assessment of the status of the thyroid.

• BMB Reports
• /
• 제45권12호
• /
• pp.677-685
• /
• 2012

In the process of tumorigenesis, normal cells are remodeled to cancer cells and protein expression patterns are changed to those of tumor cells. A newly formed tumor microenvironment elicits the immune system and, as a result, a humoral immune response takes place. Although the tumor antigens are undetectable in sera at the early stage of tumorigenesis, the nature of an antibody amplification response to antigens makes tumor-associated autoantibodies as promising early biomarkers in cancer diagnosis. Moreover, the recent development of proteomic techniques that make neo-epitopes of tumor-associated autoantigens discovered concomitantly has opened a new area of 'immuno-proteomics', which presents tumor-associated autoantibody signatures and confers information to redefine the process of tumorigenesis. In this article, the strategies recently used to identify and validate serum autoantibodies are outlined and tumor-associated antigens suggested until now as diagnostic/prognostic biomarkers in various tumor types are reviewed. Also, the meaning of autoantibody signatures and their clinical utility in personalized medicine are discussed.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권17호
• /
• pp.7959-7965
• /
• 2015

Background: Identification of predictive markers for the efficacy of platinum-based chemotherapy is necessary to improve the quality of the life of cancer patients. Materials and Methods: We detected proteins recognized by autoantibodies in pretreated sera from patients with lung adenocarcinoma (AC) evaluated as showing progressive disease (PD) or a partial response (PR) after cisplatin-based chemotherapy by proteomic analysis. Then, the levels of the candidate autoantibodies in the pretreated serum were validated by dot-blot analysis for 22 AC patients who received platinum-based chemotherapy, and the expression of identified proteins was immunohistochemically analyzed in 40 AC biopsy specimens. Results: An autoantibody against galectin-3 (Gal-3) was detected in pretreated sera from an AC patient with PD. Serum IgG levels of anti-Gal-3 autoantibody were significantly higher in patients evaluated with PD than in those with PR and stable disease (SD) (p = 0.0084). Furthermore, pretreated biopsy specimens taken from patients evaluated as showing PD following platinumbased chemotherapy showed a tendency to have a higher positive rate of Gal-3 than those with PR and SD (p = 0.0601). Conclusions: These results suggest that serum IgG levels of anti-Gal-3 autoantibody may be useful to predict the efficacy of platinum-based chemotherapy for patients with lung AC.

• 대한핵의학회지
• /
• 제21권2호
• /
• pp.133-141
• /
• 1987

To evaluate the values of the thyroid autoantibody measured by radioimmunoassay (RIA) and compare it with hemagglutination method (HA) in the normal and the thyroid disease, data were obtained from total 618 persons; 236 healthy persons, 217 patients with Graves' disease (including 113 patients with undertreated Graves' disease), 100 Hashimoto's disease, 31 thyroid nodule, and 34 simple goiter. RSR kit made in England was used and could be detected to at least 3 U/ml. The positive rates of normal group were antimicrosomal antibody (AMA) 31.8%, antithyroglobulin antibody (ATA) 44.5% by RIA and there was no considerable change in sex and age distribution. In Graves' disease, the positive rates of AMA and ATA were 90.4, 76.9% by RIA, 85, 39% by HA. In Hashimoto's disease, 94,91 % by RIA, and 87,48% by HA, respectively. The autoantibody titer by RIA in thyroid autoimmune disease as well as in normal group was more senisitive than that by HA, especially in ATA. There were linear relationships between the titer of RIA and that of HA in AMA of Graves' disease and AMA and ATA of Hashimoto's disease. There was no relationship among thyroid autoantibody, free $T_4$ index, TBII, and TSH. The titers of AMA and ATA were found to decrease in patients with Graves' disease during the course of antithyroid drug therapy. Of the 236 normal subjects, thirty-seven (15.7%) had concentrations of above 7.5 U/ml in AMA, forty. four (18.6%) above 9 U/ml in ATA. These values were considered as the upper limit for the normal range. In Graves' disease, 82.7, 53.8% were above 7.5, 9 U/ml, respectively; In Hashimoto's disease, 82, 79% were positive. We conclude that RIA was more sensitve than HA in measuring the thyoird autoantibody, but we will study further more for determining the normal range and its interpretation.

• 한국독성학회:학술대회논문집
• /
• 한국독성학회 2002년도 Molecular and Cellular Response to Toxic Substances
• /
• pp.178-179
• /
• 2002

GX-12 is a naked DNA vaccine developed by Dong-A Pharmaceutical Company, Green Cross Company and Genexine for the treatment of HIV infection. GX-12 consists of four separate plasmids. This study was performed to investigate the autoimmunogenic potential of GX-12 using primary and secondary PLNA method, and to examine the induction of autoantibodies in mice immunized with GX-12.(omitted)

• IMMUNE NETWORK
• /
• 제14권1호
• /
• pp.38-44
• /
• 2014

K/BxN serum can transfer arthritis to normal mice owing to the abundant autoantibodies it contains, which trigger innate inflammatory cascades in joints. Little is known about whether gut-residing microbes affect host susceptibility to autoantibody-mediated arthritis. To address this, we fed C57BL/6 mice with water containing a mixture of antibiotics (ampicillin, vancomycin, neomycin, and metronidazol) for 2 weeks and then injected them with K/BxN serum. Antibiotic treatment significantly reduced the amount of bacterial genomic DNA isolated from fecal samples, in particular a gene encoding 16S ribosomal RNA derived from segmented filamentous bacteria. Arthritic signs, as indicated by the arthritic index and ankle thickness, were significantly attenuated in antibiotic-treated mice compared with untreated controls. Peyer's patches and mesenteric lymph nodes from antibiotic-treated mice contained fewer IL-17-expressing cells than those from untreated mice. Antibiotic treatment reduced serum C3 deposition in vitro via the alternative complement pathway. IL-$17^{-/-}$ congenic C57BL/6 mice were less susceptible to K/BxN serum-transferred arthritis than their wild-type littermates, but were still responsive to treatment with antibiotics. These results suggest that gut-residing microbes, including segmented filamentous bacteria, induce IL-17 production in GALT and complement activation via the alternative complement pathway, which cause the host to be more susceptible to autoantibody-mediated arthritis.

• Childhood Kidney Diseases
• /
• 제6권1호
• /
• pp.120-122
• /
• 2002

IgA신병증으로 말기 신부전에 도달한 B형 혈액형의 9세 남아가 O형 혈액형의 아버지로부터 신이식을 시행받았다. 환아는 16개월 간 복막 투석 중이었으며 이전에 수혈받은 병력은 없었다. 이식 9일째 혈관내 용혈이 발견되었으며 항 B 항체 형성이 확인되었다. 저자들은 공여자의 신장과 함께 이동한 림프구가 일으킨 자가 면역 용혈성 빈혈로 진단하고 사이클로스포린 투여를 중단하였다. 용혈성 빈혈은 회복되었으나 이식 18일째 이식 신 기능 저하가 발견되어 이식 신생검을 시행하여 급성 거부를 확인하고 스테로이드 충격 요법을 시행하였다. 저자들은 ABO 부적합 신이식 후 발생한 용혈성 빈혈 1례를 겅험하여 보고하는 바이다.

• Molecular & Cellular Toxicology
• /
• 제2권1호
• /
• pp.67-73
• /
• 2006

In previous studies, it has been discovered that cancer cells not only overexpress regulatory subunit I (Rl)/protein kinase type I (PKA-I) but also secrete outside the cell an extracellular form of PKA (ECPKA) and that the ECPKA secretion detected in patients' serum is obviously greater than that found in non-cancer patients or healthy subjects. We now found that ECPKA elicits the formation of serum autoantibodies that can serve as a cancer diagnostic and prognostic marker. To measure the presence of anti-ECPKA autoantibody in the human sera, basic methodology for ECPKA assay was established an enzyme-linked immunosorbent assay (ELISA). We obtained serum samples from 199 patients with different types of cancer, and also obtained 31 serum samples to compare with ECPKA concentrations from non-cancer patients and 119 normal volunteers. Compared with normal or non-cancer patient sera, we found that the frequency of anti-ECPKA autoantibody was significantly higher in cancer patients (88%) than in those without cancer (17%). Furthermore the presence of anti-ECPKA autoantibodies in the serum of cancer patients was highly correlated with the site of metastasis. The immunoassay developed for anti-ECPKA antibodies is highly sensitive and specific. Therefore, this discovery of an autoantibody-based cancer diagnostic may have serious clinical application and may become an important advance over current technology.